Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Primary bone tumours are rare, accounting for < 0.2% of malignant neoplasms registered in the EUROCARE (European Cancer Registry based study on survival and care of cancer patients) database. Different bone tumour subtypes have distinct patterns of incidence, and each has no more than 0.3 incident cases per 100 000 per year. Osteosarcoma (OS) and Ewing sarcoma (ES) have a relatively high incidence in the second decade of life, whereas chondrosarcoma (CS) is more common in older age.

[1]  D. Campanacci,et al.  Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial. , 2018, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[2]  P. Sorensen,et al.  Ewing Sarcoma , 2020, Sarcomas.

[3]  J. Blay,et al.  Results of randomized, placebo (PL)-controlled phase II study evaluating efficacy and safety of regorafenib (REG) in patients (pts) with metastatic osteosarcoma (metOS), on behalf of the French Sarcoma Group (FSG) and Unicancer. , 2018 .

[4]  O. Mir,et al.  Interventional radiology: Role in the treatment of sarcomas. , 2018, European journal of cancer.

[5]  J. Whelan,et al.  Osteosarcoma, Chondrosarcoma, and Chordoma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Bielack,et al.  EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma , 2018, Tumori.

[7]  L. Tang,et al.  Efficacy and safety of stereotactic radiosurgery for pulmonary metastases from osteosarcoma: Experience in 73 patients , 2017, Scientific Reports.

[8]  F. Bertucci,et al.  Improved survival using specialized multidisciplinary board in sarcoma patients , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Matthew D. Young,et al.  The driver landscape of sporadic chordoma , 2017, Nature Communications.

[10]  C. Antonescu,et al.  Sarcomas With CIC-rearrangements Are a Distinct Pathologic Entity With Aggressive Outcome: A Clinicopathologic and Molecular Study of 115 Cases , 2017, The American journal of surgical pathology.

[11]  J. Blay,et al.  Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF). , 2017, European Journal of Cancer.

[12]  J. Blay,et al.  Giant cell tumour of bone in the denosumab era. , 2017, European journal of cancer.

[13]  S. Komune,et al.  Histological and immunohistochemical characteristics of undifferentiated small round cell sarcomas associated with CIC-DUX4 and BCOR-CCNB3 fusion genes , 2017, Virchows Archiv.

[14]  P. A. Gardner,et al.  Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  Katherine E Henson,et al.  Cardiac Mortality Among 200 000 Five-Year Survivors of Cancer Diagnosed at 15 to 39 Years of Age , 2016, Circulation.

[16]  K. S. Hall,et al.  Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial , 2016, The Lancet. Oncology.

[17]  J. Blay,et al.  Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial. , 2016, The Lancet. Oncology.

[18]  A. Liede,et al.  Population-based study of giant cell tumor of bone in Sweden (1983-2011). , 2016, Cancer epidemiology.

[19]  U. Dirksen,et al.  Efficacy of busulfan-melphalan high dose chemotherapy consolidation (BuMel) in localized high-risk Ewing sarcoma (ES): Results of EURO-EWING 99-R2 randomized trial (EE99R2Loc). , 2016 .

[20]  I. Lewis,et al.  UK Guidelines for the Management of Bone Sarcomas , 2010, Sarcoma.

[21]  D. de Ruysscher,et al.  Proton Therapy in Children: A Systematic Review of Clinical Effectiveness in 15 Pediatric Cancers. , 2016, International journal of radiation oncology, biology, physics.

[22]  S. Ferrari,et al.  Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone , 2016, BMC Cancer.

[23]  R. Grimer,et al.  The prognostic and therapeutic factors which influence the oncological outcome of parosteal osteosarcoma. , 2015, The bone & joint journal.

[24]  U. Dirksen,et al.  Ewing Sarcoma: Current Management and Future Approaches Through Collaboration. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  S. Chanock,et al.  Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite , 2015, Nature Genetics.

[26]  J. Blay,et al.  Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)† , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  F. Bray,et al.  Bone cancer incidence by morphological subtype: a global assessment , 2015, Cancer Causes & Control.

[28]  M. Sydes,et al.  Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  D. Biau,et al.  Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study. , 2015, European journal of cancer.

[30]  S. Stacchiotti,et al.  Building a global consensus approach to chordoma: a position paper from the medical and patient community. , 2015, The Lancet. Oncology.

[31]  P. Petit,et al.  Radiofrequency Ablation of Metastases from Osteosarcoma in Patients Under 25 Years: The SCFE Experience , 2015, Pediatric hematology and oncology.

[32]  K. S. Hall,et al.  EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment† , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  P. Casali,et al.  Sorafenib and everolimus combination in non-resectable high-grade osteosarcoma progressing after standard treatment: a non-randomized phase II clinical trial from the Italian Sarcoma Group. Abstract , 2022 .

[34]  Steven S. Wong,et al.  Regional variation and challenges in estimating the incidence of giant cell tumor of bone. , 2014, The Journal of bone and joint surgery. American volume.

[35]  P. Rosset,et al.  Adjuvant treatment with zoledronic acid after extensive curettage for giant cell tumours of bone. , 2014, European journal of cancer.

[36]  W. Wallace,et al.  Fertility preservation for girls and young women with cancer: population-based validation of criteria for ovarian tissue cryopreservation , 2014, The Lancet. Oncology.

[37]  B. Yeap,et al.  Long‐term results of Phase II study of high dose photon/proton radiotherapy in the management of spine chordomas, chondrosarcomas, and other sarcomas , 2014, Journal of surgical oncology.

[38]  K. Skubitz.  Giant Cell Tumor of Bone: Current Treatment Options , 2014, Current Treatment Options in Oncology.

[39]  S. Wild,et al.  Subsequent hospitalisation experience of 5-year survivors of childhood, adolescent, and young adult cancer in Scotland: a population based, retrospective cohort study , 2013, British Journal of Cancer.

[40]  E. Weiderpass,et al.  Descriptive epidemiology of Kaposi sarcoma in Europe. Report from the RARECARE project. , 2013, Cancer epidemiology.

[41]  M. Stratton,et al.  Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone , 2013, Nature Genetics.

[42]  David M. Thomas,et al.  Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. , 2013, The Lancet. Oncology.

[43]  Robin L. Jones,et al.  An evaluation of [F‐18]‐fluorodeoxy‐D‐glucose positron emission tomography, bone scan, and bone marrow aspiration/biopsy as staging investigations in Ewing Sarcoma , 2013, Pediatric blood & cancer.

[44]  K. Verstraete,et al.  Dynamic contrast-enhanced MR imaging for differentiation between enchondroma and chondrosarcoma , 2013, European Radiology.

[45]  F. Bertucci,et al.  Advanced chondrosarcomas: role of chemotherapy and survival. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  W. Mendenhall,et al.  Radiotherapy in the Management of Giant Cell Tumor of Bone , 2010, American journal of clinical oncology.

[47]  C. Stiller,et al.  Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. , 2013, European journal of cancer.

[48]  P. Dileo,et al.  Is [F-18]-fluorodeoxy-D-glucose positron emission tomography of value in the management of patients with craniofacial bone sarcomas undergoing neo-adjuvant treatment? , 2014, BMC Cancer.

[49]  J. Healey,et al.  Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  A. McTiernan,et al.  Incidence and survival of malignant bone sarcomas in England 1979–2007 , 2012, International journal of cancer.

[51]  M. McGirt,et al.  Posterior-only approach for en bloc sacrectomy: clinical outcomes in 36 consecutive patients. , 2012, Neurosurgery.

[52]  Gerald Antoch,et al.  Oncologic PET/MRI, Part 2: Bone Tumors, Soft-Tissue Tumors, Melanoma, and Lymphoma , 2012, The Journal of Nuclear Medicine.

[53]  S. Ferrari,et al.  153Samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[54]  R. Rostomily,et al.  Current surgical outcomes for cranial base chordomas: cohort study of 95 patients. , 2012, Neurosurgery.

[55]  R. Stupp,et al.  Phase II study of imatinib in advanced chordoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  J. Wathen,et al.  Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003. , 2012, The oncologist.

[57]  M. Yasuda,et al.  Chordomas of the skull base and cervical spine: clinical outcomes associated with a multimodal surgical resection combined with proton-beam radiation in 40 patients , 2012, Neurosurgical Review.

[58]  U. Dirksen,et al.  Risk of recurrence and survival after relapse in patients with Ewing sarcoma , 2011, Pediatric blood & cancer.

[59]  R. Grimer,et al.  The 'other' bone sarcomas: prognostic factors and outcomes of spindle cell sarcomas of bone. , 2011, The Journal of bone and joint surgery. British volume.

[60]  R. Grimer,et al.  The final diagnosis in patients with a suspected primary malignancy of bone. , 2011, The Journal of bone and joint surgery. British volume.

[61]  W. Winkelmann,et al.  The influence of tumor- and treatment-related factors on the development of local recurrence in osteosarcoma after adequate surgery. An analysis of 1355 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[62]  S. Ferrari,et al.  Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[63]  D. Vanel,et al.  Periosteal osteosarcoma , 2011, Cancer.

[64]  F. Sim,et al.  Giant Cell Tumor of Bone: Risk Factors for Recurrence , 2011, Clinical orthopaedics and related research.

[65]  Henry Z. Montes,et al.  TNM Classification of Malignant Tumors, 7th edition , 2010 .

[66]  R. Grimer,et al.  Earlier diagnosis of bone and soft-tissue tumours. , 2010, The Journal of bone and joint surgery. British volume.

[67]  U. Dirksen,et al.  Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  T. Triche,et al.  Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  S. Bielack,et al.  The role of interferons in the treatment of osteosarcoma , 2010, Pediatric blood & cancer.

[70]  U. Dirksen,et al.  The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES) , 2010, Cancer.

[71]  P. Hogendoorn,et al.  Epidemiology of primary bone tumors and economical aspects of bone metastases , 2010 .

[72]  A. Llombart‐Bosch,et al.  Molecular Diagnosis of Ewing Sarcoma Family of Tumors: A Comparative Analysis of 560 Cases With FISH and RT-PCR , 2009, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[73]  Alessandra Bolsi,et al.  Effectiveness and safety of spot scanning proton radiation therapy for chordomas and chondrosarcomas of the skull base: first long-term report. , 2009, International journal of radiation oncology, biology, physics.

[74]  R. Scholten,et al.  Prognostic factors in localized extremity osteosarcoma: a systematic review. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[75]  B. Massimo,et al.  Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high‐risk osteosarcoma patients , 2009 .

[76]  B. Yeap,et al.  Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. , 2009, International journal of radiation oncology, biology, physics.

[77]  W. Tap,et al.  Utilization of positron emission tomography in the management of patients with sarcoma , 2009, Current opinion in oncology.

[78]  D. Vanel,et al.  Response to high‐dose ifosfamide in patients with advanced/recurrent Ewing sarcoma , 2009, Pediatric blood & cancer.

[79]  Saskia Le Cessie,et al.  Assessment of Interobserver Variability and Histologic Parameters to Improve Reliability in Classification and Grading of Central Cartilaginous Tumors , 2009, The American journal of surgical pathology.

[80]  D. Heymann.  Bone Cancer Progression and Therapeutic Approaches , 2009 .

[81]  S. Ferrari,et al.  Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high‐risk osteosarcoma patients , 2009, Cancer.

[82]  L. Mariani,et al.  Chordoma of the Mobile Spine and Sacrum: A Retrospective Analysis of a Series of Patients Surgically Treated at Two Referral Centers , 2009, Annals of Surgical Oncology.

[83]  W. Winkelmann,et al.  Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  J. Eary,et al.  Imaging guidelines for children with Ewing sarcoma and osteosarcoma: A report from the Children's Oncology Group Bone Tumor Committee , 2008, Pediatric blood & cancer.

[85]  P. Hogendoorn,et al.  Results of Diagnostic Review in Pediatric Bone Tumors and Tumorlike Lesions , 2008, Journal of pediatric orthopedics.

[86]  A. Feydy,et al.  Diagnostic imaging of solitary tumors of the spine: what to do and say. , 2008, Radiographics : a review publication of the Radiological Society of North America, Inc.

[87]  B. Freidlin,et al.  Complexities in interpretation of osteosarcoma clinical trial results. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  S. Bielack,et al.  Mesenchymal chondrosarcoma of soft tissues and bone in children, adolescents, and young adults , 2008, Cancer.

[89]  P. Leavey,et al.  Ewing sarcoma: prognostic criteria, outcomes and future treatment , 2008, Expert review of anticancer therapy.

[90]  N. Willich,et al.  Whole Lung Irradiation in Patients with Exclusively Pulmonary Metastases of Ewing Tumors , 2008, Strahlentherapie und Onkologie.

[91]  H. Gelderblom,et al.  The clinical approach towards chondrosarcoma. , 2008, The oncologist.

[92]  Paul A Meyers,et al.  Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  P. Hogendoorn,et al.  Incidence of Biopsy-Proven Bone Tumors in Children: A Report Based on the Dutch Pathology Registration "PALGA" , 2008, Journal of pediatric orthopedics.

[94]  R. Grimer,et al.  Do pathological fractures influence survival and local recurrence rate in bony sarcomas? , 2007, European journal of cancer.

[95]  D. Biau,et al.  Dedifferentiated chondrosarcoma: prognostic factors and outcome from a European group. , 2007, European journal of cancer.

[96]  Michael Scholz,et al.  Effectiveness of carbon ion radiotherapy in the treatment of skull-base chordomas. , 2007, International journal of radiation oncology, biology, physics.

[97]  M. van Glabbeke,et al.  Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. , 2007, Journal of the National Cancer Institute.

[98]  M. Hansen,et al.  Osteosarcoma in Paget's Disease of Bone , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[99]  T. Peabody,et al.  Staging of Primary Malignancies of Bone , 2006, CA: a cancer journal for clinicians.

[100]  H. Jürgens,et al.  Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors , 2006, Pediatric blood & cancer.

[101]  S. Bielack,et al.  Current strategies of chemotherapy in osteosarcoma , 2006, International Orthopaedics.

[102]  S. Henderson,et al.  Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas , 2006, The Journal of pathology.

[103]  M. Link,et al.  Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--a report from the Children's Oncology Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  S. Bielack,et al.  Periosteal osteosarcoma--a European review of outcome. , 2005, European journal of cancer.

[105]  S. Ferrari,et al.  Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[106]  F. Sim,et al.  Operative management of sacral chordoma. , 2005, The Journal of bone and joint surgery. American volume.

[107]  A. Cleton-Jansen,et al.  Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. , 2005, The Lancet. Oncology.

[108]  M. Semik,et al.  Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[109]  M. Nooij,et al.  Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study. , 2005, European journal of cancer.

[110]  J. Habrand,et al.  Radiotherapeutic Factors in the Management of Cervical-basal Chordomas and Chondrosarcomas , 2004, Neurosurgery.

[111]  F. Sim,et al.  Dedifferentiated chondrosarcoma: the role of chemotherapy with updated outcomes. , 2004, The Journal of bone and joint surgery. American volume.

[112]  T. Bauer,et al.  Recommendations for the reporting of bone tumors. Association of Directors of Anatomic and Surgical Pathology. , 2004, Human pathology.

[113]  S. Bielack,et al.  Delaying surgery with chemotherapy for osteosarcoma of the extremities , 2004, Expert opinion on pharmacotherapy.

[114]  E. Pignotti,et al.  Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992. , 2004, European journal of cancer.

[115]  W. Winkelmann,et al.  Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[116]  M. Link,et al.  Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[117]  S. Donaldson,et al.  Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. , 2003, The New England journal of medicine.

[118]  S. Ferrari,et al.  Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[119]  W. Winkelmann,et al.  Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. , 2003, International journal of radiation oncology, biology, physics.

[120]  S. Ferrari,et al.  High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[121]  B. Fuchs,et al.  Etiology of osteosarcoma. , 2002, Clinical orthopaedics and related research.

[122]  W. Winkelmann,et al.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[123]  F. Mertens,et al.  World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone , 2002 .

[124]  W. Winkelmann,et al.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[125]  D. Vanel,et al.  Computed tomography of pulmonary metastases from osteosarcoma: the less poor technique. A study of 51 patients with histological correlation. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[126]  C. Dykewicz.  Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[127]  A. Craft,et al.  Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[128]  A. Craft,et al.  Incidence and survival for cancer in children and young adults in the North of England, 1968–1995: a report from the Northern Region Young Persons’ Malignant Disease Registry , 2000, British Journal of Cancer.

[129]  J. Bloem,et al.  Cartilaginous tumors: fast contrast-enhanced MR imaging. , 2000, Radiology.

[130]  D. Vanel,et al.  Imaging Evaluation of the Response of High-Grade Osteosarcoma and Ewing Sarcoma to Chemotherapy with Emphasis on Dynamic Contrast-Enhanced Magnetic Resonance Imaging , 2000, Seminars in musculoskeletal radiology.

[131]  S. Ferrari,et al.  Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[132]  M. van Glabbeke,et al.  Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone: A European Osteosarcoma Intergroup study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[133]  C. Arndt,et al.  Common musculoskeletal tumors of childhood and adolescence. , 1999, The New England journal of medicine.

[134]  Richard A. Szucs,et al.  TNM Classification of Malignant Tumors. 5th ed , 1998 .

[135]  J. Bloem,et al.  Preoperative evaluation and monitoring chemotherapy in patients with high-grade osteogenic and Ewing’s sarcoma: review of current imaging modalities , 1998, Skeletal Radiology.

[136]  K. Verstraete,et al.  Osteosarcoma and Ewing's sarcoma after neoadjuvant chemotherapy: value of dynamic MR imaging in detecting viable tumor before surgery. , 1995, AJR. American journal of roentgenology.

[137]  P. Picci,et al.  Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[138]  H. Kovar,et al.  Variability of EWS chimaeric transcripts in Ewing tumours: a comparison of clinical and molecular data. , 1994, British Journal of Cancer.

[139]  P. Sorensen,et al.  A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS–family transcription factor, ERG , 1994, Nature Genetics.

[140]  E. Gehan,et al.  Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[141]  E. Gehan,et al.  Ewing's sarcoma metastatic at diagnosis results and comparisons of two intergroup Ewing's sarcoma studies , 1990, Cancer.

[142]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[143]  A. Aurias,et al.  Translocation involving chromosome 22 in Ewing's sarcoma. A cytogenetic study of four fresh tumors. , 1984, Cancer genetics and cytogenetics.

[144]  H. Mankin,et al.  The hazards of biopsy in patients with malignant primary bone and soft-tissue tumors. , 1982, The Journal of bone and joint surgery. American volume.

[145]  W. Enneking,et al.  A System for the Surgical Staging of Musculoskeletal Sarcoma , 1980, Clinical orthopaedics and related research.